Images | Sources | Experiment + Assay | Phenotypes | Human Diseases | ||||
---|---|---|---|---|---|---|---|---|
Fig. 2B B'B'' E E'E''
Kreis J et al. (2021) |
Xla Wt + rab7a MO
NF13 (in situ hybridization) |
|
||||||
Fig. 8A
Wang YH et al. (2015) |
Xla.Tg(hsp70:grem1,cryga-RFP) + HS
NF51 (in situ hybridization) |
|
||||||
fig.8.f
Liu C et al. (2012) |
Xla Wt + map3k7 MO
NF10-10.25 (in situ hybridization) |
|
||||||
fig.7.f
Belyaeva OV et al. (2012) |
Xla Wt + sdr16c5 MO
NF14 (in situ hybridization) |
|
||||||
fig.3.e
Peyrot SM et al. (2011) |
Xla Wt + Cyclopamine
NF16 (in situ hybridization) |
|
||||||
fig.3.e
Peyrot SM et al. (2011) |
Xla Wt + shh MO
NF16 (in situ hybridization) |
|
||||||
fig.2.c, c^1
Peyrot SM et al. (2011) |
Xla Wt + canotch1
NF16 (in situ hybridization) |
|
||||||
fig.2.d, d^1
Peyrot SM et al. (2011) |
Xla Wt + canotch1
NF16 (in situ hybridization) |
|
||||||
fig.2.f
Peyrot SM et al. (2011) |
Xla Wt + canotch1
NF16 (in situ hybridization) |
|
||||||
fig.2.g, h
Peyrot SM et al. (2011) |
Xla Wt + canotch1
NF16 (in situ hybridization) |
|